Test Code MAFP1 Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum
Necessary Information
In order to provide the best results, either answer the order entry questions or provide the required information using the Second Trimester Maternal Screening Alpha-Fetoprotein / Quad Screen Patient Information (T595).
Specimen Required
Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions:
1. Do not collect specimen after amniocentesis as this could affect results.
2. Centrifuge and aliquot serum into plastic vial within 2 hours of collection.
Additional Information:
1. Collect blood between 15 weeks, 0 days and 22 weeks, 6 days.
2. Initial or repeat testing is determined in the laboratory at the time of report and will be reported accordingly. To be considered a repeat test for the patient, the testing must be within the same pregnancy and trimester, with interpretable results for the same test, and both tests are performed at Mayo Clinic.
Forms
1. Second Trimester Maternal Screening Alpha-Fetoprotein / Quad Screen Patient Information (T595) is required
2. If not ordering electronically, complete, print, and send a General Request (T239)
Useful For
Prenatal screening for open neural tube defect
Special Instructions
Method Name
Two-Site Immunoenzymatic (Sandwich) Assay
Reporting Name
AFP Single Marker SCRN, Maternal, SSpecimen Type
SerumSpecimen Minimum Volume
0.5 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 14 days | |
Frozen | 90 days | ||
Ambient | 7 days |
Reference Values
NEURAL TUBE DEFECTS:
An alpha-fetoprotein (AFP) multiple of the median (MoM) <2.5 is reported as screen negative.
AFP MoM ≥2.5 (singleton and twin pregnancies) are reported as screen positive.
An interpretive report will be provided.
Interpretation
Neural tube defects:
A screen-negative result indicates that the calculated alpha-fetoprotein (AFP) multiple of the median (MoM) falls below the established cutoff of 2.50 MoM. A negative screen does not guarantee the absence of neural tube defects (NTD).
A screen-positive result indicates that the calculated AFP MoM is 2.50 or greater and may indicate an increased risk for open NTD. The actual risk depends on the level of AFP and the individual's pretest risk of having a child with NTD based on family history, geographical location, maternal conditions such as diabetes and epilepsy, and use of folate prior to conception. A screen-positive result does not infer a definitive diagnosis of a NTD but indicates that further evaluation should be considered. Approximately 80% of pregnancies affected with an open NTD have elevated AFP MoM values greater than 2.50.
Follow up:
Upon receiving maternal serum screening results, all information used in the risk calculation should be reviewed for accuracy (ie, weight, diabetic status, gestational dating). If any information is incorrect the laboratory should be contacted for a recalculation of the estimated risks.
Screen-negative results typically do not warrant further evaluation.
Ultrasound is recommended to confirm dates for NTD screen-positive results. If ultrasound yields new dates that differ by at least 7 days, a recalculation should be considered. If dates are confirmed, high-resolution ultrasound and amniocentesis (including amniotic fluid AFP and acetylcholinesterase measurements for NTD) are typically offered.
Clinical Reference
1. Christensen RL, Rea MR, Kessler G, Crane JP, Valdes R Jr: Implementation of a screening program for diagnosing open neural tube defects: selection, evaluation, and utilization of alpha-fetoprotein methodology. Clin Chem. 1986 Oct;32(10):1812-1817
2. American College of Obstetricians and Gynecologists: Practice Bulletin No. 163: Screening for Fetal Aneuploidy. Obstet Gynecol. 2016 May;127(5):e123-137
3. Zhang J, Lambert-Messerlian G, Palomaki GE, Canick JA: Impact of smoking on maternal serum markers and prenatal screening in the first and second trimesters. Prenat Diagn. 2011 Jun;31(6):583-588
4. Yarbrough ML, Stout M, Gronowski AM: Pregnancy and its disorders. In: Rifai N, Horvath AR, Wittwer CT, eds. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 6th ed. Elsevier; 2018:1655-1696
Day(s) Performed
Monday through Friday
Report Available
4 to 6 daysPerforming Laboratory
Mayo Clinic Laboratories in RochesterTest Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
82105
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
MAFP1 | AFP Single Marker SCRN, Maternal, S | 48802-3 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
7058 | Recalculated Maternal Serum Screen | 32399-8 |
113146 | Results Summary | 32399-8 |
113147 | Neural tube defect risk estimate | 48803-1 |
10351 | AFP | 83073-7 |
113148 | AFP MoM | 23811-3 |
10356 | INTERPRETATION | 49092-0 |
10357 | RECOMMENDED FOLLOW UP | 80615-8 |
10248 | Additional comments | 48767-8 |
3009 | Specimen collection date | 33882-2 |
7823 | Maternal date of birth | 21112-8 |
7834 | Calculated age at EDD | 43993-5 |
26717 | Maternal Weight | 29463-7 |
26718 | Maternal Weight | 29463-7 |
IDD | Insulin dependent diabetes | 44877-9 |
RACE1 | Patient race | 21484-1 |
SMKNG | Current cigarette smoking status | 64234-8 |
10054 | EDD by U/S scan | 11781-2 |
7203 | GA on collection by U/S scan | 11888-5 |
7753 | EDD by LMP | 11779-6 |
7204 | GA on collection by dates | 11885-1 |
7830 | GA used in risk estimate | 21299-3 |
MULTF | Number of Fetuses | 55281-0 |
CHOR_ | Number of Chorions | 92568-5 |
IVFP | IVF pregnancy | 47224-1 |
PRNTD | Prev Pregnancy w/ Neural Tube Defect | 53827-2 |
PTNTD | Patient or father of baby has a NTD | 53827-2 |
INTL | Initial or repeat testing | 77202-0 |
DRPHN | Physician Phone Number | 68340-9 |
10358 | GENERAL TEST INFORMATION | 62364-5 |